IMMUQUAD BIOSCIENCES
Immuquad Biosciences was founded by a research team from the University of Chicago in the United States. It is a national high-tech enterprise that focuses on changing the diagnosis and treatment of diseases by decoding the adaptive immune system, and is committed to promoting the development of immune-driven medicine . . Aimuan is at the forefront of adaptive immune system research. The self-developed immune medicine platform can reveal and translate the genetic code of the adaptive immune system and can be applied to immune-mediated diseases such as cancer, autoimmune diseases, and infectious diseases. in the diagnosis, monitoring, and treatment of sexually transmitted diseases.
IMMUQUAD BIOSCIENCES
Industry:
Biotechnology Health Care Life Science
Website Url:
http://www.immuquad.com
Status:
Active
Official Site Inspections
http://www.immuquad.com
- Host name: 121.40.253.228
- IP address: 121.40.253.228
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Immuquad Biosciences"
艾沐蒽® – 免疫驱动医学解决方案
T细胞免疫测评. Immun-Cheq ® | T细胞免疫测评通过简单的采集血液样本，对受试者的免疫细胞受体基因进行二代测序和生物信息学临床分析后，获得的免疫细胞的多态性和克隆性，从而判断 …See details»
关于我们 – 艾沐蒽® - immuquad.com
杭州艾沐蒽生物科技有限公司由美国芝加哥大学科研团队回国创办，是一家专注于通过解码适应性免疫系统来改变疾病的诊断和治疗，并致力于推进 免疫驱动医学 领域发展的 国家级高新技术 …See details»
ImmuQuad Biotech - Crunchbase Company Profile & Funding
Organization. ImmuQuad Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... ImmuQuad Biotechnologies, based in …See details»
Hangzhou ImmuQuad Biotechnologies, LLC: Drug pipelines, …
Jun 20, 2023 Explore Hangzhou ImmuQuad Biotechnologies, LLC with its drug pipeline, therapeutic area, technology platform, .See details»
ImmuQuad Biotech - PitchBook
ImmuQuad Biotech General Information Description. Developer of immune-driven medicine designed to innovate the diagnosis and treatment of disease. The company focuses on …See details»
Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC. | LinkedIn
Hangzhou ImmuQuad Biotech focuses on immune system and cancers. We provide human T cell and B cell receptor repertoire NGS with bioinformatics analysis services and Neo-antigen TCR …See details»
ImmuQuad Biotech - Contacts, Employees, Board Members
ImmuQuad Biotechnologies is a leading national high-tech enterprise in the field of immunogenomics (TCR/BCR) technology.See details»
ImmuQuad Biotech - Tech Stack, Apps, Patents & Trademarks
Nov 10, 2024 Organization. ImmuQuad Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech …See details»
Genetron Health Enters Exclusive Global Licensing Agreement with ...
Oct 22, 2020 ImmuQuad is eligible to receive high single-digit royalties on product sales for 10 years following commercialization. Separately, Genetron Health has made a minority equity …See details»
ImmuQuad Biotech - Products, Competitors, Financials, Employees ...
ImmuQuad Biotech specializes in immunogenomics and provides high-throughput sequencing analysis for immune cell receptors. Use the CB Insights Platform to explore ImmuQuad …See details»
Genetron Health Enters Exclusive Global Licensing Agreement with ...
Oct 22, 2020 Collaboration and equity investment to provide Genetron Health with significant know-how in immune profiling and accelerate MRD product development in hematologic …See details»
ImmuQuad Biotech - Crunchbase
ImmuQuad Biotechnologies is a leading national high-tech enterprise in the field of immunogenomics (TCR/BCR) technology. Search Crunchbase. Start Free Trial . Chrome …See details»
ImmuHub®免疫组测序服务焕新体验｜TCR & BCR七链联检， …
公司地址 浙江省杭州市上城区石桥路196号浙江省农业科创园4楼1层 邮编：310000 联系电话See details»
公司新闻 – 艾沐蒽® - immuquad.com
Nov 28, 2024 艾沐蒽生物科技提供免疫组库(tcr/bcr)二代基因测序服务See details»
Genetron licenses Immuquad’s MRD assays in hematologic cancer
Oct 30, 2020 Precision oncology company Genetron Holdings Ltd. has entered an exclusive licensing agreement for Seq-MRD, a diagnostic assay for detecting and monitoring minimal …See details»
Genetron Health Enters Exclusive Global Licensing Agreement
Oct 22, 2020 ImmuQuad is eligible to receive high single-digit royalties on product sales for 10 years following commercialization. Separately, Genetron Health has made a minority equity …See details»
Genetron Health Licenses ImmuQuad Technology for Blood …
Oct 22, 2020 ImmuQuad is eligible to receive high single-digit royalties on product sales for 10 years following commercialization. Genetron has also made a minority equity investment in in …See details»
ImmuQuad Biotech - Funding, Financials, Valuation & Investors
Oct 1, 2020 How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 1, 2020: …See details»
Quantitative Analysis of Thymus-Independent Donor-Derived T …
4 Hangzhou ImmuQuad Biotechnologies, LLC, Hangzhou, China; Zhejiang-California International NanoSystems Institute, Zhejiang University, Hangzhou, China. Electronic address: …See details»
Series A - ImmuQuad Biotech - 2020-10-01 - Crunchbase
Oct 1, 2020 Series A - ImmuQuad Biotech . Save . Summary. Overview. Edit Overview Section. Organization Name . ImmuQuad Biotech . Announced Date Oct 1, 2020; Funding Type Series …See details»